Sarepta Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sarepta Therapeutics sits in the top decile of US sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count).
Sarepta Therapeutics: 33 sponsored US clinical trials, 1 recruiting.
Sarepta Therapeutics sponsors 33 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 19 completed. 7 of these trials are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Muscular Dystrophy, Duchenne, with 3 trials.
Top-decile sponsor footprint
Sarepta Therapeutics ranks in the top decile of sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 27 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
33 total, page 1 of 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
NCT04626674
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
NCT06246513
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
NCT05881408
A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
NCT05876780
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
NCT04475926
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
NCT03992430
Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States
NCT06747273
A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74
NCT06597656
A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)
NCT05906251
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
NCT05096221
Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
NCT04004065
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)
NCT03675126
A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)
NCT03769116
Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)
NCT03652259
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
NCT03532542
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)
NCT03375255
A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
NCT03375164
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
NCT02500381
rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies
NCT02710500
Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
NCT02530905
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
NCT02420379
Phase I/II Study of SRP-4053 in DMD Patients
NCT02310906
Study of Eteplirsen in DMD Patients
NCT02255552
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
NCT02286947
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers
NCT01566877
Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy
NCT01540409
Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients
NCT01396239
Safety Study of Single Administration Intravenous Treatment for Influenza
NCT01375985
Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus
NCT01353040
Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
NCT01353027
Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020
NCT00387283
Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid
NCT00381433
Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid
NCT00343148
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 20 |
| Phase 2 | 5 |
| Phase 3 | 7 |
Therapeutic Areas
What is open in the Sarepta Therapeutics pipeline
1 recruiting of 33 indexed (3% open); 19 completed (58%).
Phase mix: 7 late (III/IV) vs 25 early (I/II) (early-phase heavy).
Top condition: Muscular Dystrophy, Duchenne (3 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sarepta Therapeutics: open-pipeline peers nationwide
Peers matched on 33 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Sarepta Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 33 trials (± recruiting share)
- Aclaris Therapeutics · 33 trials · 3% recruiting
- Antonios Likourezos · 33 trials · 12% recruiting
- Baylor University · 33 trials · 15% recruiting
- Becton, Dickinson and Company · 33 trials · 3% recruiting
Sponsors near 3% open enrollment (± trial volume)
- National Center for Complementary and Integrative Health (NCCIH) · 3% recruiting · 203 trials
- Idorsia Pharmaceuticals · 3% recruiting · 34 trials
- Klein Buendel · 3% recruiting · 34 trials
- Kyowa Kirin · 3% recruiting · 34 trials
Related
What to do with this Sarepta Therapeutics page
33 registered trials is a research-attention snapshot, not an endorsement of Sarepta Therapeutics or any single study.
- 1 of Sarepta Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Muscular Dystrophy, Duchenne is the condition Sarepta Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Muscular Dystrophy, Duchenne trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sarepta Therapeutics pipeline card: 33 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.